The efficacy of antithrombin administration in the acute phase of burn injury

Thrombosis and Haemostasis

Volumn 100, Issue 2, 2008, Pages 286-290

  Lavrentieva, Athina ^a   Kontakiotis, Theodore ^b,c   Bitzani, Militsa ^a   Parlapani, Aggeliki ^b   Thomareis, Olympia ^b   Scourtis, Harisios ^b   Tsotsolis, Nicolaos ^b   Lazaridis, Lambis ^b   Giala, Maria Amalia ^b  

^a Department of Hematology and Bone Marrow Transplantation   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c NONE   (Greece)

Author keywords

Antithrombin; Burn injury; Coagulation markers; Disseminated intravascular coagulation; Sequential organ failure assessment score

Indexed keywords

ANTITHROMBIN; D DIMER; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ABSENCE OF SIDE EFFECTS; ADULT; ADVERSE OUTCOME; ARTICLE; BLOOD CLOTTING; BURN; CLINICAL ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; HEMATOLOGIC DISEASE; HUMAN; INTENSIVE CARE UNIT; MALE; MORTALITY; PRIORITY JOURNAL; THERMAL INJURY;

ACUTE DISEASE; ADULT; AGED; ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BURNS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRINOLYSIS; HUMANS; INCIDENCE; INTENSIVE CARE; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THROMBIN; TREATMENT OUTCOME;

EID: 48949094355     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-11-0684     Document Type: Article

References (35)

1. Aoki K, Aikawa N, Sekine K, et al. Elevation of plasma free PAI-1 levels as an integrated endothelial response to severe burns. Burns 2001; 27: 569-575.
2. Niedermayr M, Schramm W, Kamolz L, et al. Antithrombin deficiency and its relationship to severe burns. Burns 2007; 33: 173-178.
3. Garcia-Avello A, Lorente JA, Cesar-Perez J, et al. Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma. Thromb Res 1998; 89: 59-64.
4. Barret JP, Gomez PA. Disseminated intravascular coagulation: a rare entity in burn injury. Burns 2005; 31: 354-357.
5. Soejima K, Schmalstieg FC, Sakurai H, et al. Pathophysiological analysis of combined burn and smoke inhalation injuries in sheep.Am J Physiol Lung Cell Mol Physiol 2001; 280: L1233-1241.
6. Kowal-Vern A, Gamelli RL, Walenga JM, et al. The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical state. J Trauma 1992; 33: 50-57.
7. Wells S, Sissons M, Hasleton PS. Quantitation of pulmonary megakaryocytes and fibrin thrombi in patients dying from burns. Histopathology 1984; 8: 517-527.
8. Murakami K, McGuire R, Cox RA, et al. Recombinant antithrombin attenuates pulmonary inflammation following smoke inhalation and pneumonia in sheep. Crit Care Med 2003; 31: 577-583.
9. Kowal-Vern A, Walenga JM, McGill V, et al. The impact of antithrombin (H) concentrate infusions on pulmonary function in the acute phase of thermal injury. Burns 2001; 27: 52-60.
10. Kowal-Vern A, Latenser BA. Antithrombin (human) concentrate infusion in pediatric patients with >50% TBSA burns. Burns 2003; 29: 615-618.
11. Eisele B, Lamy M. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure. Semin Thromb Hemost 1998; 24: 71-80.
12. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
13. Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998; 89: 233-241.
14. Hoffmann JN, Vollmar B, Romisch J, et al. Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium. Crit Care Med 2002; 30: 218-225.
15. Pulletz S, Lehmann C, Volk T, et al. Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. Crit Care Med 2000; 28: 2881-2886.
16. Roemisch J, Gray E, Hoffmann JN, et al. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13: 657-670.
17. Niessen RW, Lamping RJ, Jansen PM, et al. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 1997; 78: 1088-1092.
18. Taylor FB Jr, Toh CH, Hoots WK, et al.; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-1330.
19. Smith GW, Gamelli RL, Shankar R. Hematologic, Hematopoetic, and Acute Phase Response; In: Total Burn Care, 3rd edition, W.B. Saunders, Harcourt Publishers Ltd. 2006: 325-342.
20. Enkhbaatar P, Traber LD, Traber DL. Antithrombin in burn trauma. In: Yearbook of Intensive Care and Imergency Medicine, Springer, 2007: 791-796.
21. Mavrommatis AC, Theodoridis T, Economou M, et al. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Intensive Care Med 2001; 27: 1853-1859.
22. Roman J, Velasco F, Fernandez F, et al. Coagulation, fibrinolytic and kallikrein systems in neonates with uncomplicated sepsis and septic shock. Haemostasis 1993; 23: 142-148.
23. Lorente JA, Garcia-Frade LJ, Landin L, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103: 1536-1542.
24. Kowal-Vern A, Walenga JM, Levi M, et al. Significance of the PAP complex in thermal injury. Clinical Appl Thromb Hemost 1995; 1: 210-214.
25. Asakura H, Ontachi Y, Mizutani T, et al. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation.. Crit Care Med 2001; 29: 1164-1168.
26. Aoki K, Nishino N, Baba S, et al. Postoperative changes in plasma tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. Surg Today 1994; 24: 1039-1043.
27. Watanabe R, Wada H, Watanabe Y, et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001; 104: 1-6.
28. Okabayashi K, Wada H, Ohta S, et al. Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol 2004; 76: 225-229.
29. Kountchev J, Bijuklic K, Bellmann R, et al. Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis. Crit Care 2005; 9: R596-600.
30. Fourrier F, Leclerc F, Aidan K, et al. Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study. Intensive Care Med 2003; 29: 1081-1087.
31. Ilias W, List W, Decruyenaere J, et al. Antithrombin III in patients with severe sepsis: a pharmacokinetic study. Intensive Care Med 2000; 26: 704-715.
32. Paternoster DM, Fantinato S, Manganelli F, et al. Efficacy of AT in pre-eclampsia: a case-control prospective trial. Thromb Haemost 2004; 91: 283-289.
33. Nishiyama T. Antithrombin can modulate coagulation, cytokine production, and expression of adhesion molecules in abdominal aortic aneurysm repair surgery. Anesth Analg 2006; 102: 1007-1011.
34. Warren BL, Eid A, Singer P, et al.; KyberSept Trial Study G Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc 2001; 286: 1869-1878.
35. Kienast J, Juers M, Wiedermann CJ, et al.; Kyber-Sept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4: 90-97.